highly significantP < 0.001
These agents produced highly significant reductions (* P < 0.001) from the early stages of treatment and maintained superior efficacy throughout the 28-day study period.
These agents produced highly significant reductions (* P < 0.001) from the early stages of treatment and maintained superior efficacy throughout the 28-day study period.